Testing tirabrutinib against a two-drug combination for primary CNS lymphoma that came back
Original title: IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a large late stage trial, so the treatment is being tested in many people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial compares one drug, tirabrutinib, with a two-drug treatment in people whose primary central nervous system lymphoma has come back or did not respond.
Who this trial is for. This trial is for people with primary central nervous system lymphoma, a cancer that starts in the brain or spinal cord. It is for people whose cancer came back or did not respond to earlier treatment. The trial gives some people tirabrutinib on its own. Others get a combination of two drugs, rituximab and temozolomide.
Where it stands. This trial has not reported results. The team is measuring how well tirabrutinib works compared with the two-drug combination. They are also watching how safe it is. The answer is not in yet.
What this means, and what it doesn't
What it could mean: If your lymphoma came back after treatment, this is one of the options being tested right now. Someone who thinks they might fit could ask their care team about it. The care team can help you understand whether a trial like this makes sense for your situation.
What it doesn't mean: This does not mean tirabrutinib is a proven treatment. A trial is a test. Nobody knows yet whether one approach works better than the other. Being in a trial is not a guarantee that you will be helped. It is not a promise of a cure. Whether anyone can join is decided by the trial team.
Source: ClinicalTrials.gov, August 5, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.